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Primary bone lymphoma (PBL) is an uncommon clinical entity and a rare presentation of non-Hodgkin's
lymphoma. PBL accounts for less than 5% of malignant bone tumors, 4–5% of extra nodal lymphoma and
less than 1% of all non-Hodgkin's lymphoma. Diffuse large-B-cell lymphoma (DLBCL) accounts for the
majority of cases of PBL. The incidence of PBL is so rare that many of its aspects remain unknown.
A number of studies have been reported fromwestern countries but only a few reports are available from
Asia. Out of 20,000 bone lesions received in our department over 5 years, only 5 cases were primary bone
lymphoma; all of which were DLBCL. We report our experience on PBLs with main emphasis on two
unusual presentations of this rare tumor.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
According to WHO classiﬁcation, PBL is deﬁned as a mono-
ostotic disease with or without involvement of regional lymph
nodes, or as a poly-ostotic disease affecting multiple skeletal sites
without visceral- or lymph node involvement [1].
Primary lymphoma of bone is an uncommon clinical entity and
accounts for less than 5% of malignant bone tumors, 4–5% of extra
nodal lymphoma and less than 1% of all non-Hodgkin's lymphoma.
Diffuse large-B-cell lymphoma (DLBCL) accounts for the majority
of cases of PBL [2]. The varied clinical and histopathological
proﬁles of PLB are still to be explored entirely.2. Methods
A 5 year study (2006–2011) of all primary lymphomas of bone
were undertaken retrospectively and prospectively in our depart-
ment. Cases with unusual presentation were studied in detail
along with their immunohistochemical proﬁle. In all patients,
staging evaluation included hematological and chemical survey,
in addition to chest X-rays, abdominal ultrasonography, computed
tomography of the chest and abdomen, and bone marrow biopsy.
Cases were staged according to the Ann Arbor staging system [3].
Complete data on followup was not available due to either
inability of patient to complete followup or referral of patient to. This is an open access article und
L, Diffuse large B cellsome higher/cancer speciality center. The patients were treated
with combined radiochemotherapy. The dose of radiation therapy
was between 35 and 45 Gy, and CHOP chemotherapy regimen was
employed. Complete Response (CR) was deﬁned as disappearance
of all evidence of lymphoma, as documented by a normal physical
examination, blood tests, and radiologic imaging. When residual
radiographic abnormalities were consistent with normal bone
reformation, patients were considered in CR if no other possible
signs of disease were present. Partial Response (PR) was deﬁned as
450% reduction in tumor burden without CR after completion of
treatment, and no response as anything else. Local failure was
deﬁned as failure in the initial bone site and/or in adjacent
lymphnodes. Failure anywhere outside these conﬁnes was con-
sidered to be distant [4].3. Observations and results
Out of 20,000 bone lesions received in our department over 5
years from 2006 to 2011, 360 (1.8%) were neoplastic out of which
11 were bone lymphomas. Of the 11 cases of bone lymphomas,
6 cases were secondary involvement by non-Hodgkin's lymphoma
and 5 cases were primary bone lymphoma. All the 5 cases of
primary bone lymphoma (PBL) were Diffuse large B-cell lym-
phoma (DBCL) type, 3 of which presented in pelvis(60%), 1 each in
femur (20%) and mandible (20%). 3 cases were of usual and 2 had
unusual presentation or morphology. Table 1 summarizes the
clinic-pathological characteristics of the patients described in
this study.
The ﬁrst unusual presentation (case 4) was a 65-year-old man
who presented with the chief complaints of intermittent fever,er the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tion, multiple draining sinuses were present on right side of jaw.
A CT scan of the jaw revealed a breach in the cortex of the mandible
on the right side [Fig. 1]. A presumptive diagnosis of tubercular
osteomyelitis was made and draining ﬂuid was sent for AFB stain,
results came were negative. A biopsy was sent for histopathological
examination, which revealed diffuse inﬁltration of the skin, sub-
cutaneous tissue and muscle with lymphoid cells [Fig. 2]. Immu-
nohistochemistry was positive for LCA, CD20, Ki 67 (50–60%) and
negative for CD3 and CD4 [Fig. 3]. Hence a diagnosis of diffuse large
B cell lymphoma of the mandible was made and the patient was
started on CHOP chemotherapy regimen followed by radiotherapy
to which he is responding well. Additional investigations did not
show any other bony lesions or lymphnode involvement.
The second peculiar presentation (case 5) was a 54-year-male
who complained of pain and swelling of right hip since 5 months
with increasing intensity. On examination the patient had restricted
movements of left hip joint and a lump could be palpated. X-ray
showed soft tissue and bony mass involving the right ileum [Fig. 4].
A presumptive clinicoradiological diagnosis of chondrosarcoma was
made and biopsy was performed. Histopathological examination
showed small round cell tumor cells in a sclerotic stroma [Fig. 4].
Immunohistochemistry of the lesion showed positivity for LCA, CD
20, CD10,Vimentin, Bcl-2, Bcl-6, PAX-5, MUM1, Ki-67 (70–80%) andTable 1
Clinico-pathological characteristics of patients described in the study.
Sl. no. Age Sex Site Diagnosis Stage Followup
1 55 M PELVIS DLBCL I E Referred
2 47 F PELVIS DLBCL II E Lost
3 59 M FEMUR DLBCL II E PR
4 65 M MANDIBLE DLBCL I E CR, no. failure at 1 year
5 54 M PELVIS DLBCL I E Referred
Fig. 1. CT scan revealed brea
Fig. 2. Diffuse inﬁltration onegative for CD 99, Pancytokeratin, Desmin, CD-3, S-100, CD-5,
HMB-45 [Fig. 5]. The morphology and immunophenotype was
compatible with the diagnosis of diffuse large B cell lymphoma
and suggest a follicle center cell origin. So a ﬁnal diagnosis of diffuse
large B cell lymphoma of right ileum was made. No additional bony
or lymphnode involvement was found. The patient was advised
CHOP chemotherapy followed by radiotherapy.4. Discussion
Primary lymphoma of bone is a rare disease, ﬁrst described by
Oberling in 1928 and he labeled it as reticulum cell sarcoma of
bone because of the presence of characteristic reticulin ﬁbers
within the lesion [5]. This work was followed by Parker and
Jackson and later by Ivin and Boston who, eventually established
the distinct entity of this lesion and labeled it as the malignant
lymphoma of bone [6,7]. The use of immunohistochemistry in
highlighting the cellular origin of these lymphomas was described
by Vassallo in 1987 [8]. Even till today, the diagnosis of these
lesions remains challenging and requires the help of immunohis-
tochemical markers along with histopathology to lead to the ﬁnal
diagnosis.
The deﬁnition of PLB varies throughout the literature. Generally,
this entity is deﬁned as malignant lymphoma arising within the
medullary cavity of a single bone without concurrent regional
lymph node or visceral involvement [9]. In contrast, Shoji and
Miller permitted regional lymph node metastases but stipulated
that the interval between the onset of symptoms of the primary
focus and the appearance of distant metastases should be greater
than 6 months [10]. The vast majority of these lymphomas are non-
Hodgkin lymphoma (NHL), the common subtype being diffuse large
B cell lymphoma. In addition to DLBCL, other lymphoid malignan-
cies may manifest with primary bone presentation, includingch in mandibular cortex.
f large B-cells. (H&E).
Fig. 3. IHC: POSITVE: A – CD20, B – LCA, D – Ki67- (50–60%); NEGATIVE: C – CD3.
Fig. 4. A: Lytic lesion of right ileum; B and C – small round cells with a sclerotic background (H&E).
Fig. 5. IHC: POSITIVE: A – BCL2, D – CD20, E – BCL6, F – PAX5, G – MUM-1,H – Ki67; NEGATIVE: B – CD5 C – CD3.
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lymphomas, B-cell lymphoplasmacytic lymphomas, anaplastic large
cell lymphomas, peripheral T-cell lymphomas, HL and precursor
B-cell lymphoblastic lymphomas [11]. Primary Hodgkin lymphoma
(HL)of bone is extremely rare, and the majority of patients have
concurrent nodal involvement at presentation [12].
Clinically, the most commonly affected age group is 20–50
years with a male preponderance (male: female¼3:2). Femur
(29%) is the most common site affected followed by pelvis (19%),
humerus (13%), skull (11%) and tibia (10%) [13]. Heyning FH [10]
reported femur to be the most common site of involvement
whereas Susnerwala et al. [14] found pelvis to be the most
common site which is consistent with our study. Three out of ﬁve
cases had involvement of pelvis. Median age of diagnosis was 37
years with male:female ratio 4.9:1 in study by Susnerwala et al.
[14] whereas median age of diagnosis was 56 years with male:
female ratio of 4:1 in our study.
Local pain and swelling are usually the most common present-
ing complaints [15] but multiple discharging sinuses has rarely
been seen as a feature as was seen in one of our cases which was
misleading towards an infectious etiology. Radiologically, there
exists a wide spectrum of ﬁndings ranging from a normal appear-
ing bone to an extensive, destructive or inﬁltrative lesion. The
destructive lesions are patchy, radiolucent, mottled, moth eaten
and occasionally exhibit complete loss of the outline. This may be
accompanied by cortical bone thickening and destruction in 25% of
cases and occasionally large soft-tissue extension [9].
Apart from histopathology, which still remains the mainstay of
diagnosis, numerous investigations which aid in diagnosis are skeletal
survey, bone scan, bone marrow biopsy, CT scan of whole abdomen
and chest to assess lymph node involvement and serum LDH estima-
tion done as part of the staging procedure. With the combined use of
CT, MRI and now PET scan, a higher proportion of patients are
diagnosed with stage IV disease [10]. The differential diagnosis of
PBL are metastatic carcinoma, Ewing's sarcoma, osteosarcoma, eosi-
nophilic granuloma (skeletal) and chronic osteomyelitis [11] and needs
to be differentiated from them. The present study emphasizes that it is
the wide range of immunohistochemical markers that offers the ﬁnal
rescue in cases with atypical morphology.
PBL was deﬁned as a separate disease entity in the realm of
lymphoma on the notion of a comparably favorable outcome. This
tumor has a signiﬁcantly different clinical course and a much
better prognosis than Non-Hodgkin's Lymphoma (NHL), seconda-
rily affecting bone. Radiotherapy is an effective modality for good
local control due to its radio-responsiveness, but distant failures
occur in approximately 50% of initially localized bone tumors. Thus
employment of adjuvant systemic chemotherapy in a multimod-
ality approach is warranted for improvement of results [14].
In contrast to adults, PBL in children is regarded as a clinical
entity that is distinct from its adult counterpart. Like many other
pediatric malignancies, PBL is considered a systemic disease in
children. In small retrospective studies, PBL in children is char-
acterized by rapid progression, a higher incidence of micrometas-
tasis, and a propensity for spread to the central nervous system,
yet children have a better prognosis [16].
In a multivariate analysis, adult patients who had local disease
and who were younger had a signiﬁcant survival advantage.
Similarly, there was a signiﬁcant association between young age
and a histological classiﬁcation of “NHL-Large B-cell diffuse”. A
survival analysis of patients with localized disease revealed that
radiation therapy was associated with improved survival, whereas
surgery did not prove to be of survival beneﬁt [16]. A current study
[16] supports sub-classiﬁcation of group of patient with PBL who
have localized disease because there is a difference in their
prognosis and outcome compared with patients who have other,
more extensive disease.In this paper, we promulgate our experience of PBL with emp-
hasis on their unusual presentations, one of which had abnormal
clinical presentation and the other had abnormal morphology of the
cells and emphasize that DLBCL is to be kept in mind while dealing
with any bony lesions.5. Conclusion
PBL in itself is a rare tumor with a comparably favorable outcome
and only few studies having been done on it. Therefore, its varied
clinical and histopathological proﬁles are still to be explored entirely.
We report our experience on PBLs and highlight two unusual
presentations along with emphasizing the fact that although PBL is
a rare entity, still it should be kept in mind while dealing with
bone lesions especially in the setting of an unusual presentation.
A ﬁnal diagnosis should be made only after proper clinical,
radiological, ancillary studies, histopathological and immunohis-
tochemical correlation.
The locally limited PBL should be differentiated from poten-
tially systemic variant because they have different characteristics
with regard to clinical outcome. There is a need to further analyze
the local and systemic PBL separately.Submission declaration
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